"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

GSK PLC GSK shares advanced 3.35% to £14.02 Monday, on what proved to be an all-around great trading session for the stock ...

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

Sheryl Lee Ralph exclusively told Us Weekly she is ready to reunite with Denzel Washington for an 'adult rom-com' ...

Bearish flow noted in GSK (GSK) Pharma with 1,694 puts trading, or 4x expected. Most active are 2/7 weekly 34 puts and Jan-27 28 puts, with total volume in those strikes near 1,600 contracts. The ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...

Shares of GSK PLC GSK inched down 0.51% to £13.57 Friday, on what proved to be an all-around poor trading session for the ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...